Timoma ve Timik Karsinom
Özet
Timoma ve timik karsinom, timüs epitel tümörleri arasında nadir görülen ancak uzun vadede ciddi takip gerektiren malignitelerdir. Timoma daha az agresif seyrederken, timik karsinom daha kötü prognoza sahip ve nüks riski yüksek bir tümördür. Tedavi sonrası takip, hastalığın nüksünü erken tespit etmek ve otoimmün komplikasyonları yönetmek açısından kritik öneme sahiptir. Standart takip protokolü, intravenöz kontrastlı bilgisayarlı tomografi (BT) ile düzenli görüntüleme yapılmasını içerir. Evre I timoma ve timik karsinom vakalarında ilk iki yıl boyunca 6 ayda bir, sonrasında timoma için 10 yıl, timik karsinom için 5 yıl yıllık BT ile takip önerilir. Daha ileri evre vakalarda bu sıklık, ilk iki yıl boyunca 3-6 ayda bir kontrastlı BT olacak şekilde artırılmalıdır. Nüksler genellikle cerrahiden sonraki ilk 3 ila 7 yıl içinde görülür ve tam cerrahi çıkarım sağkalımı olumlu etkiler. Rezeke edilemeyen nükslerde kemoterapi ve radyoterapi seçenekleri değerlendirilmelidir. Takip sürecinde sekonder malignite gelişme riski de artmıştır ve timoma hastalarında lenfoma, gastrointestinal kanserler ve yumuşak doku sarkomlarının daha sık görüldüğü bildirilmiştir. Takip protokolü yalnızca nükslerin değil, bu kanserlerin erken teşhisini de içermelidir. Ayrıca, otoimmün komplikasyonlar açısından özellikle miyastenia gravis takibi önemlidir ve anti-asetilkolin reseptör antikorlarının düzenli izlenmesi önerilmektedir. Ameliyat sonrası miyastenia gravis gelişimi, asemptomatik hastalarda bile ortaya çıkabilir ve bu durum takip protokollerine dahil edilmelidir. Takip sürecinde geç toksisite ve tedaviye bağlı komplikasyonlar da izlenmeli, hastaların uzun vadede düzenli aralıklarla değerlendirilmesi sağlanmalıdır. Nükslerin geç dönemlerde de görülebilmesi nedeniyle takip süreci en az 10-15 yıl sürdürülmeli ve bu süreçte moleküler hedefe yönelik tedavilerle kişiselleştirilmiş izleme protokolleri geliştirilmelidir.
Thymoma and thymic carcinoma are rare malignancies among thymus epithelial tumors but require serious long-term follow-up. While thymoma is less aggressive, thymic carcinoma has a worse prognosis and a high risk of recurrence. Post-treatment follow-up is critical for early detection of disease recurrence and management of autoimmune complications. The standard follow-up protocol includes regular imaging with intravenous contrast-enhanced computed tomography (CT). In stage I thymoma and thymic carcinoma cases, follow-up with CT is recommended every 6 months for the first two years, then every 10 years for thymoma and every 5 years for thymic carcinoma. In more advanced cases, this frequency should be increased to every 3-6 months for the first two years with contrast-enhanced CT. Recurrences are usually seen within the first 3 to 7 years after surgery, and complete surgical removal positively affects survival. Chemotherapy and radiotherapy options should be considered in unresectable recurrences. The risk of developing secondary malignancies has also increased during the follow-up period, and lymphoma, gastrointestinal cancers, and soft tissue sarcomas have been reported to be more common in thymoma patients. The follow-up protocol should include not only recurrences but also early diagnosis of these cancers. In addition, myasthenia gravis follow-up is especially important in terms of autoimmune complications, and regular monitoring of anti-acetylcholine receptor antibodies is recommended. Postoperative myasthenia gravis development can occur even in asymptomatic patients, and this should be included in follow-up protocols. Late toxicity and treatment-related complications should also be monitored during the follow-up period, and patients should be evaluated at regular intervals in the long term. Since recurrences can also be seen in the late stages, the follow-up period should be continued for at least 10-15 years, and personalized monitoring protocols should be developed with molecular targeting treatments during this period.
Referanslar
De Jong WK, Blaauwgeers JL, Schaapveld M et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44: 123–130.
Travis WB, Brambilla A, Muller-Hermelinck HK, Marx A. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: Travis WB (ed), World Health Organization Classification of Tumours. Lyon: IARC Press 2004; p. 146.
Marx A, Ströbel P, Badve SS et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol 2014; 9: 596–611
Kojima Y, Ito H, Hasegawa S et al. Resected invasive thymoma with multiple endocrine neoplasia type 1. Jpn J Thorac Cardiovasc Surg 2006; 54: 171–173.
Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105: 546–551.
Seki S, Koyama H, Ohno Y et al. Diffusion-weighted MR imaging vs. multi-detector row CT: direct comparison of capability for assessment of management needs for anterior mediastinal solitary tumors. Eur J Radiol 2014; 83: 835–842.
Evoli A, Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol 2014; 9(Suppl 2): S143–S147.
Marx A, Hohenberger P, Hoffmann H et al. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 2010; 5(Suppl 4): S266–S272.
Nakajima J, Okumura M, Yano M, Date H, Onuki T, Haniuda M, Sano Y; Japanese Association for Research of Thymus. Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database. Eur J Cardiothorac Surg. 2016 May;49(5):1510-5. doi: 10.1093/ejcts/ezv380. Epub 2015 Nov 3. PMID: 26537756.
Nakajima J, Okumura M, Yano M, Date H, Onuki T, Haniuda M, Sano Y; Japanese Association for Research of Thymus. Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database. Eur J Cardiothorac Surg. 2016 May;49(5):1510-5. doi: 10.1093/ejcts/ezv380. Epub 2015 Nov 3. PMID: 26537756.
Nakajima J, Murakawa T, Fukami T, et al. Postthymectomy myasthenia gravis: relationship with thymoma and antiacetylcholine receptor antibody. Ann Thorac Surg. 2008;86(3):941-5
Carter BW, Marom EM, Detterbeck FC. Approaching the patient with an anterior mediastinal mass: a guide for clinicians. J Thorac Oncol 2014; 9(Suppl 2): S102–S109.
Ackman JB, Verzosa S, Kovach AE et al. High rate of unnecessary thymectomy and its cause. Can computed tomography distinguish thymoma, lymphoma, thymic hyperplasia, and thymic cysts? Eur J Radiol 2015; 84: 524–533.
Priola AM, Priola SM, Ciccone G et al. Differentiation of rebound and lymphoid thymic hyperplasia from anterior mediastinal tumors with dual-echo chemical-shift MR imaging in adulthood: reliability of the chemical-shift ratio and signal intensity index. Radiology 2015; 274: 238–249.
Henschke CI, Lee IJ, Wu N et al. CT screening for lung cancer: prevalence and incidence of mediastinal masses. Radiology 2006; 239: 586–590
Evans AG, French CA, Cameron MJ et al. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012; 36: 222–1227.
Kaira K, Endo M, Abe M et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D- glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28: 3746–3753.
Marchevsky A, Marx A, Ströbel P et al. Policies and reporting guidelines for small biopsy specimens of mediastinal masses. J Thorac Oncol 2011; 6(Suppl 3): S1724–S1729.
Wang H, Sima CS, Beasley MB et al. Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy. Arch Pathol Lab Med 2014; 138: 658–663.
Den Bakker MA, Roden AC, Marx A, Marino M. Histologic classification of thymoma: a practical guide for routine cases. J Thorac Oncol 2014; 9(Suppl 2): S125–S130.
Detterbeck FC, Nicholson AG, Kondo K et al. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol 2011; 6(Suppl 3): S1710–S1716.
Detterbeck F. Towards a TNM based prognostic classification for thymic tumours. J Thorac Oncol 2013; 8(Suppl 2): S68 (abst. MS16.2).
Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011; 6(Suppl 3): S1698–S1704.
Detterbeck FC, Stratton K, Giroux D et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9(Suppl 2): S65–S72.
Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011; 6(Suppl 3): S1698–S1704.
Marom EM, Milito MA, Moran CA et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol 2011; 6: 1274–1281.
. Zhao Y, Chen H, Shi J et al. The correlation of morphological features of chest computed tomographic scans with clinical characteristics of thymoma. Eur J Cardiothorac Surg 2014 [Epub ahead of print].
Huang J, Detterbeck FC, Wang Z, Loehrer PJ, Sr. Standard outcome measures forthymic malignancies. J Thorac Oncol 2011; 6(Suppl 3): S1691–S1697.
Detterbeck FC, Moran C, Huang J et al. Which way is up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thoracic Oncol 2011; 6(Suppl 3): S1730–S1738.
Forquer JA, Rong N, Fakiris AJ et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010; 76: 440–445.
Patel S, Macdonald OK, Nagda S et al. Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys 2012; 82: 1797–1801.
Ahmad U, Yao X, Detterbeck F et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg 2015; 149: 95–100.
Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 2009; 87: 1641–1647.
Falkson CB, Bezjak A, Darling G et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4: 911–919.
Girard N, Mornex F, Van Houtte P et al. Thymoma: a focus on current therapeutic management. J Thorac Oncol 2009; 4: 119–126.
Attaran S, McCormack D, Pilling J, Harrison-Phipps K. Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy? Interact Cardiovasc Thorac Surg 2012; 15: 273–275.
Berruti A, Borasio P, Gerbino A et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81: 841–845.
Girard M, Lal R, Wakelee H et al. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol 2011; 6(7 Suppl 3): S1749–S1755.
Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 2012; 12: 685–695.
Kim ES, Putnam JB, Komaki R et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004; 44: 369–379.
Wright CD. Extended resections for thymic malignancies. J Thorac Oncol 2010; 5(10 Suppl 3): S344–S347.
Yellin A, Simansky DA, Ben-Avi R et al. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single- institution experience. J Thorac Cardiovasc Surg 2013; 145: 83–87.
Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma. Ann Thorac Surg 2006; 82: 1234–1239.
Hamaji M, Kojima F, Omasa M et al. A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg 2015; 47: 602–607.
Okuma Y, Saito M, Hosomi Y et al. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 2015; 141: 323–331.
Hirai F, Yamanaka T, Taguchi K et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 2015; 26: 363–368
Benveniste MF, Korst RJ, Rajan A et al. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol 2014; 9: S119–S124
Loehrer PJ, Sr, Chen M, Kim K et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997; 15: 3093–3099
NCCN Clinical Practice Guidelines in Oncology. Thymomas and Thymic Carcinomas V.1.2025.
Sandri A, Cusumano G, Lococo F et al. Long-term results after treatment for recurrent thymoma: a multicenter analysis. J Thorac Oncol 2014; 9: 1796–1804.
Mizuno T, Okumura M, Asamura H et al. Surgical management of recurrent thymic epithelial tumors: a retrospective analysis based on the Japanese nationwide database. J Thorac Oncol 2015; 10: 199–205.
Lara PN, Jr, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest 1996; 110: 1115–1117.
Lemma GL, Lee JW, Aisner SC et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29: 2060–2065.
Palmieri G, Merola G, Federico P et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010; 21: 1168–1172
Loehrer PJ, Yiannoutsos CT, Dropcho S et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006; 24(Suppl 18): abstr 7079.
Loehrer PJ, Sr, Wang W, Johnson DH et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293–299
Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol 2014; 9(Suppl 2): S131–S136.
Giaccone G, Rajan A, Ruijter R et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009; 4: 1270–1273.
Salter JT, Lewis D, Yiannoutsos C et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008; 26(15s suppl): abstr 8116.
Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105. doi: 10.1016/S1470-2045(15)70095-1. PMID: 25592632; PMCID: PMC4401497
Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol. 2020 Jun;21(6):843-850. doi: 10.1016/S1470-2045(20)30162-5. PMID: 32502444
Conforti F, Zucali PA, Pala L, Catania C, Bagnardi V, Sala I, Della Vigna P, Perrino M, Zagami P, Corti C, Stucchi S, Barberis M, Guerini-Rocco E, Di Venosa B, De Vincenzo F, Cordua N, Santoro A, Giaccone G, De Pas TM. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 Oct;23(10):1287-1296. doi: 10.1016/S1470-2045(22)00542-3. Epub 2022 Sep 9. PMID: 36096156.
Zucali PA, De Pas TM, Palmieri G et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2014; 32 (5s suppl): abstr 7527.
Arunachalam A, Zhang I, Zhao B, et al. Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis. Lung Cancer 2023; 176:132.
Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018; 19:347.
Giaccone G, Kim C. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol 2021; 16:483.
Margaritora S, Cesario A, Cusumano G, et al. Single-center 40-year results of recurrence surgery for recurrent thymomas. Eur J Cardiothorac Surg.
Hamaji M, Allen MS, Cassivi SD, et al. The role of surgical treatment in recurrent thymic tumors. 2012;94(1):247-54.
Hamaji M, Ali SO, Burt BM. Meta-analysis of surgical and non-surgical treatments in the treatment of recurrent thymoma. 2014;98(2):748-55.
Bae MK, Byun CS, Lee CY, et al. Clinical outcomes and prognosis of treatment for recurrent thymoma 2012;7(8):1304-14.
Mizuno T, Okumura M, Asamura H, et al; Japanese Thymus Research Association. Surgical treatment of recurrent thymic epithelial tumors: a retrospective analysis based on a Japanese nationwide database 2015; 205Haniuda M, Kondo R, Numanami H, Makiuchi A, Machida E, Amano J. Recurrence of thymoma: clinicopathological features, re-operation, and outcome. J Surg Oncol. 2001 Nov;78(3):183-8. doi: 10.1002/jso.1146. PMID: 11745803.
Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003 Jul 1;105(4):546-51. doi: 10.1002/ijc.11099. PMID: 12712448
Nakajima J, Murakawa T, Fukami T, et al. Postthymectomy myasthenia gravis: association with thymoma and antiacetylcholine receptor antibody 2008;86(3):941-5.
Sakuraba M, onuki T, Nitta S. Measurement of antiacetylcholine receptor antibody in thymoma patients without complications of myasthenia gravis Jpn J Thorac Cardiovasc Surg.
Pan CC, Chen PC, Wang LS, et al. Thymoma is associated with an increased risk of second malignancy. 2001;92(9):2406-11.
Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260-5.
